JAK2 mutation and thrombosis in the myeloproliferative neoplasms

Current Hematologic Malignancy Reports

Volumn 5, Issue 1, 2010, Pages 22-28

  Vannucchi, Alessandro M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

JAK2 mutation; Leukocytosis; Myeloproliferative neoplasms; Splanchnic vein thrombosis; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2; PHENYLALANINE; VALINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART INFARCTION; AGE; ARTERY THROMBOSIS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE COURSE; GENE MUTATION; HUMAN; HYPERCOAGULABILITY; LIVER VEIN THROMBOSIS; LOW DRUG DOSE; LUNG EMBOLISM; MALIGNANT TRANSFORMATION; MESENTERIC VEIN THROMBOSIS; MORTALITY; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PATHOPHYSIOLOGY; POLYCYTHEMIA VERA; PORTAL VEIN THROMBOSIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTHEMIA; THROMBOGENESIS; THROMBOSIS; VEIN THROMBOSIS;

AMINO ACID SUBSTITUTION; ASPIRIN; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; INTERFERON-ALPHA; JANUS KINASE 2; MULTICENTER STUDIES AS TOPIC; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; POINT MUTATION; QUINAZOLINES; THROMBOPHILIA; THROMBOSIS;

EID: 76649091567     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0038-x     Document Type: Review

References (50)

1. AM Vannucchi P Guglielmelli A Tefferi 2009 Advances in understanding and management of myeloproliferative neoplasms CA Cancer J Clin 59 171 191 10.3322/caac.20009 19369682
2. A Tefferi J Thiele A Orazi, et al. 2007 Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 110 1092 1097 10.1182/blood-2007-04- 083501 17488875 1:CAS:528:DC%2BD2sXptFKmurg%3D The myeloproliferative disorders have been renamed as "myeloproliferative neoplasms" to better signify their neoplastic nature, and the presence of JAK2 or MPL mutation is included as a major diagnostic criterion. This study prompted the final draft of the 2008 World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues (Pubitemid 47281402)
3. A Tefferi 2008 The history of myeloproliferative disorders: before and after Dameshek Leukemia 22 3 13 10.1038/sj.leu.2404946 17882283
4. DE Rollison N Howlader MT Smith, et al. 2008 Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004: utilizing data from the NAACCR and SEER Programs Blood 112 45 52 10.1182/blood-2008-01-134858 18443215 1:CAS:528:DC%2BD1cXotlymu7Y%3D
5. PJ Campbell 2009 Somatic and germline genetics at the JAK2 locus Nat Genet 41 385 386 10.1038/ng0409-385 19338077 1:CAS:528:DC%2BD1MXjslartLs%3D
6. Vainchenker W, Constantinescu SN: A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program 2005, 195-200.
7. RL Levine A Pardanani A Tefferi DG Gilliland 2007 Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders Nat Rev Cancer 7 673 683 10.1038/nrc2210 17721432 1:CAS:528:DC%2BD2sXpsFSjsbg%3D (Pubitemid 47327415)
8. R Kralovics F Passamonti AS Buser, et al. 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 1779 1790 10.1056/NEJMoa051113 15858187 1:CAS:528:DC%2BD2MXjsFyhsLw%3D (Pubitemid 40570926)
9. AM Vannucchi E Antonioli P Guglielmelli, et al. 2008 Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal Leukemia 22 1299 1307 10.1038/leu.2008.113 18496562
10. LM Scott W Tong RL Levine, et al. 2007 JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis N Engl J Med 356 459 468 10.1056/NEJMoa065202 17267906 1:CAS:528:DC%2BD2sXht1ersrc%3D (Pubitemid 46193073)
11. Y Pikman BH Lee T Mercher, et al. 2006 MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia PLoS Med 3 e270 10.1371/journal.pmed.0030270 16834459 1:CAS:528:DC%2BD28XnvFymtLY%3D (Pubitemid 44125998)
12. PJ Campbell AR Green 2006 The myeloproliferative disorders N Engl J Med 355 2452 2466 10.1056/NEJMra063728 17151367 1:CAS:528:DC%2BD28Xht12nt7vN (Pubitemid 44903749)
13. F Delhommeau S Dupont V Della Valle, et al. 2009 Mutation in TET2 in myeloid cancers N Engl J Med 360 2289 2301 10.1056/NEJMoa0810069 19474426 Deletions or mutations in TET2, a novel candidate tumor-suppressor gene, were identified in 19% of patients with myelodysplastic syndromes, 12% with myeloproliferative disorders, and 24% with acute myeloid leukemia. TET2 mutations were found in hematopoietic stem cells and preceded the JAK2V617F mutation, pointing to TET2 as a pre-JAK2 molecular lesion in myeloproliferative disorders
14. AM Vannucchi P Guglielmelli 2008 Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations Haematologica 93 972 976 10.3324/haematol.13266 18591622 1:CAS:528:DC%2BD1cXhsVWis7vP (Pubitemid 351957012)
15. F Cervantes F Passamonti G Barosi 2008 Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders Leukemia 22 905 914 10.1038/leu.2008.72 18385755 1:CAS:528:DC%2BD1cXlvVSrsbY%3D (Pubitemid 351698623)
16. F Cervantes B Dupriez A Pereira, et al. 2009 New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 113 2895 2901 10.1182/blood-2008-07-170449 18988864 1:CAS:528:DC%2BD1MXktFWnsLc%3D In this international multicenter study, 1054 patients with PMF were studied with the aim of identifying clinical and hematologic variables associated with survival. Older age, constitutional symptoms, lower hemoglobin, higher leukocyte count, and circulating blast cells (1%) were identified in multivariate analysis as predictors of shortened survival. By using these variables, four classes of patients with no overlapping in their survival curves were delineated. This scoring system will be pivotal in therapeutic decisions and for inclusion of PMF patients in clinical trials.
17. S Cortelazzo G Finazzi M Ruggeri, et al. 1995 Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis N Engl J Med 332 1132 1136 10.1056/NEJM199504273321704 7700286 1:STN:280:DyaK2M3hsVKkuw%3D%3D
18. R Landolfi R Marchioli J Kutti, et al. 2004 Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 350 114 124 10.1056/NEJMoa035572 14711910 1:CAS:528:DC%2BD2cXjs1aluw%3D%3D (Pubitemid 38056222)
19. R Marchioli G Finazzi R Landolfi, et al. 2005 Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J Clin Oncol 23 2224 2232 10.1200/JCO.2005.07.062 15710945 (Pubitemid 46218714)
20. CN Harrison PJ Campbell G Buck, et al. 2005 Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia N Engl J Med 353 33 45 10.1056/NEJMoa043800 16000354 1:CAS:528:DC%2BD2MXmtVWjsbs%3D (Pubitemid 41007805)
21. F Cervantes A Alvarez-Larran E Arellano-Rodrigo, et al. 2006 Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution Leukemia 20 55 60 10.1038/sj.leu.2404048 16307011 1:STN:280:DC%2BD283hvFWguw%3D%3D
22. V De Stefano T Za E Rossi, et al. 2008 Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments Haematologica 93 372 380 10.3324/haematol.12053 18268279 1:CAS:528:DC%2BD1cXhtl2gtbbO The rate of recurrence was estimated in a multicenter cohort of 494 patients with ET or PV with previous arterial thrombosis (67.6%), venous thrombosis (31%), or both (1.4%). Thrombosis recurred in 166 patients (33.6%), with an incidence of 7.6% per patient-year. Age greater than 60 years and increased leukocyte count at the time of first thrombosis in patients less than 60 years old predicted for recurrence. Cytoreduction halved the risk in the overall cohort, and a combination regimen with antiplatelet agents or oral anticoagulants proved more effective than administration of a single drug.
23. JJ Kiladjian F Cervantes FW Leebeek, et al. 2008 The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases Blood 111 4922 4929 10.1182/blood-2007-11-125328 18250227 1:CAS:528:DC%2BD1cXmtlaiurs%3D The prognostic value of JAK2 and MPL515 mutations was assessed in 241 patients with SVT. JAK2V617F was found in almost all patients with bone marrow or progenitor-cell growth abnormalities specific for a myeloproliferative disorder but also in more than half of those with only one feature and in 7% of those with neither feature. This paper supports the utility of routine JAK2 genotyping in patients with SVT, even in the absence of clinical suspicion of MPN
24. G Finazzi T Barbui 2005 Risk-adapted therapy in essential thrombocythemia and polycythemia vera Blood Rev 19 243 252 10.1016/j.blre.2005.01.001 15963833 (Pubitemid 40814453)
25. M Marchetti A Falanga 2008 Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders Pathophysiol Haemost Thromb 36 148 159 10.1159/000175153 19176988 1:CAS:528:DC%2BD1MXhtFOmu74%3D
26. M Di Nisio T Barbui L Di Gennaro, et al. 2007 The haematocrit and platelet target in polycythemia vera Br J Haematol 136 249 259 10.1111/j.1365-2141.2006.06430.x 17156406 (Pubitemid 46020752)
27. TC Pearson G Wetherley-Mein 1978 Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia Lancet 2 1219 1222 10.1016/S0140-6736(78)92098-6 82733 1:STN:280:DyaE1M%2FntFOksQ%3D%3D
28. A Tefferi N Gangat AP Wolanskyj 2006 Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? [letter] Blood 108 2493 2494 10.1182/blood-2006-05-025544 16988161 1:CAS:528: DC%2BD28XhtVCgur3J (Pubitemid 44497538)
29. T Barbui A Carobbio A Rambaldi G Finazzi 2009 Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: Is leukocytosis a causative factor? Blood 114 759 763 19372254 1:CAS:528:DC%2BD1MXpsVCqurk%3D This illuminating critical reappraisal of recent data and of pathophysiologic mechanisms supports the relevance of leukocytosis as a risk factor for thrombosis in MPNs
30. A Carobbio G Finazzi E Antonioli, et al. 2008 Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia Blood 112 3135 3137 10.1182/blood-2008-04-153783 18587010 1:CAS:528: DC%2BD1cXht1Omur7E
31. A Falanga M Marchetti V Evangelista, et al. 2000 Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera Blood 96 4261 4266 11110700 1:CAS:528:DC%2BD3cXosl2ht7Y%3D
32. M Marchetti E Castoldi HM Spronk, et al. 2008 Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera Blood 112 4061 4068 10.1182/blood-2008-06-164087 18768782 1:CAS:528:DC%2BD1cXhsVSmsr3F The aim of this study was to define the relationships of a hypercoagulable state with JAK2V617F mutational status in ET and PV. The occurrence of activated protein C (APC) resistance was demonstrated to correlate with a JAK2V617F mutant genotype and the burden of mutant allele. APC resistance was probably due to a reduction in free protein-S levels. These data indicate that the APC-resistant phenotype is influenced by the JAK2V617F mutational load
33. E Antonioli P Guglielmelli A Pancrazzi, et al. 2005 Clinical implications of the JAK2 V617F mutation in essential thrombocythemia Leukemia 19 1847 1849 10.1038/sj.leu.2403902 16079890 1:CAS:528:DC%2BD2MXhtVags7vJ (Pubitemid 41486170)
34. E Antonioli P Guglielmelli G Poli, et al. 2008 Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia Haematologica 93 41 48 10.3324/haematol.11653 18166784 1:CAS:528:DC%2BD1cXitVOhsr4%3D (Pubitemid 351156150)
35. AP Wolanskyj TL Lasho SM Schwager, et al. 2005 JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance Br J Haematol 131 208 213 10.1111/j.1365-2141.2005.05764.x 16197451 1:CAS:528:DC%2BD2MXht1Wkt73O (Pubitemid 43899687)
36. AM Vannucchi E Antonioli P Guglielmelli, et al. 2007 Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia Blood 110 840 846 10.1182/blood-2006-12-064287 17379742 1:CAS:528:DC%2BD2sXos1CqsL4%3D To evaluate the clinical relevance of a homozygous state of the JAK2V617F mutation, 118 homozygous patients (104 PV, 14 ET) were identified in a retrospective, multicentric study. JAK2V617F homozygosity was found to be associated with a distinct clinical phenotype and more frequent evolution into secondary myelofibrosis in PV and ET. In a multivariate analysis, homozygous ET patients displayed a significantly higher risk of cardiovascular events (Pubitemid 47267419)
37. AM Vannucchi E Antonioli P Guglielmelli, et al. 2007 Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden Leukemia 21 1952 1959 10.1038/sj.leu.2404854 17625606 1:CAS:528:DC%2BD2sXptlSrsb0%3D (Pubitemid 47299969)
38. PD Ziakas 2008 Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain Haematologica 93 1412 1414 10.3324/haematol.12970 18641024
39. IJ Dahabreh K Zoi S Giannouli, et al. 2008 Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia Leuk Res 33 67 73 10.1016/j.leukres.2008.06.006 18632151 1:CAS:528:DC%2BD1cXhtlWltLjK
40. F Lussana S Caberlon C Pagani, et al. 2009 Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review Thromb Res 124 409 417 10.1016/j.thromres.2009.02.004 19299003 1:CAS:528:DC%2BD1MXhtVOju77K
41. De Stefano V, Za T, Rossi E, et al.: Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. Ann Hematol 2009 Jul 7 (Epub ahead of print).
42. V De Stefano A Fiorini E Rossi, et al. 2007 Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders J Thromb Haemost 5 708 714 10.1111/j.1538-7836.2007.02424.x 17263783 (Pubitemid 46563568)
43. F Dentali A Squizzato L Brivio, et al. 2009 JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis Blood 113 5617 5623 10.1182/blood-2008-12- 196014 19273837 1:CAS:528:DC%2BD1MXntVeru70%3D
44. M Griesshammer S Struve T Barbui 2008 Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy Blood Rev 22 235 245 10.1016/j.blre.2008.03.007 18617299
45. F Passamonti ML Randi E Rumi, et al. 2007 Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617 V∈>∈F) mutation Blood 110 485 489 10.1182/blood-2007-01-071068 17426257 1:CAS:528:DC%2BD2sXot1emsbw%3D
46. E Mercier G Lissalde-Lavigne JC Gris 2007 JAK2 V617F mutation in unexplained loss of first pregnancy N Engl J Med 357 1984 1985 10.1056/NEJMc071528 17989398 1:CAS:528:DC%2BD2sXht1ymur%2FM (Pubitemid 350074711)
47. N Gangat AP Wolanskyj S Schwager A Tefferi 2009 Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies Eur J Haematol 82 350 353 10.1111/j.1600-0609.2009.01214.x 19243425
48. IJ Dahabreh AV Jones M Voulgarelis, et al. 2009 No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage Br J Haematol 144 802 803 10.1111/j.1365-2141.2008.07510.x 19036091
49. A Falanga M Marchetti A Vignoli, et al. 2007 V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules Exp Hematol 35 702 711 10.1016/j.exphem.2007.01.053 17577920 1:CAS:528:DC%2BD2sXmt1egsrk%3D (Pubitemid 46601748)
50. A Pardanani 2008 JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials Leukemia 22 23 30 10.1038/sj.leu.2404948 17882282